What is G454?
G454 is a proposed extended-release capsule formulation of amphetamine, developed by C.L. Lannett. It is intended for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) [1].
How is G454 different from Adderall?
Adderall is a brand name for a mixed-salt amphetamine product that contains four different amphetamine salts: dextroamphetamine sulfate, dextroamphetamine saccharate, amphetamine aspartate monohydrate, and amphetamine sulfate [2]. G454 is specifically an extended-release capsule formulation of amphetamine [1]. The key difference lies in their formulation and drug release profiles. Adderall is available in both immediate-release and extended-release (Adderall XR) forms, while G454 represents a distinct extended-release formulation of amphetamine [1, 2].
When does G454's patent expire?
Information regarding the patent expiry for G454 is not publicly available through the provided source. For detailed patent information, DrugPatentWatch.com may be a useful resource [1].
What is the status of G454's development?
G454 is a product in development by C.L. Lannett. Its regulatory status and timeline for potential approval are not detailed in the provided information [1].
What are the potential benefits of extended-release amphetamine formulations?
Extended-release formulations, like the proposed G454, are designed to provide a consistent therapeutic effect over a longer period compared to immediate-release medications. This can potentially lead to more stable symptom control and reduce the need for multiple daily doses, which may improve patient adherence and convenience [1, 2].
What are the risks associated with amphetamine medications for ADHD?
Amphetamine medications, including Adderall, carry potential risks. Common side effects can include decreased appetite, insomnia, dry mouth, and weight loss. More serious risks can include cardiovascular issues, psychiatric symptoms such as hallucinations or manic episodes, and the potential for abuse and dependence [2].
How does C.L. Lannett develop new ADHD medications?
C.L. Lannett focuses on developing generic and branded pharmaceutical products, including extended-release formulations. Their development process for medications like G454 involves creating unique delivery systems for existing active pharmaceutical ingredients, aiming to offer alternative treatment options [1].
---
Sources:
1. https://drugpatentwatch.com/company/c-l-lannett
2. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021305s040,021306s035,021307s032,021308s031lbl.pdf